Fol. Biol. 2008, 54, 81-87
https://doi.org/10.14712/fb2008054030081
T Cells in the Pathogenesis of ANCA-Associated Vasculitis: Current Knowledge
References
1. 2007a) CD4-positive effector memory T cells participate in disease expression in ANCA-associated vasculitis. Ann. N. Y. Acad. Sci. 1107, 22-31.
< , W. H., Stegeman, C. A., Limburg, P. C., Kallenberg, C. G. (https://doi.org/10.1196/annals.1381.003>
2. 2007b) Functional defect of circulating regulatory CD4+ T cells in patients with Wegener’s granulomatosis in remission. Arthritis Rheum. 56, 2080-2091.
< , W. H., Stegeman, C. A., van der Geld, Y. M., Doornbos-van der Meer, B., Limburg, P. C., Kallenberg, C. G. (https://doi.org/10.1002/art.22692>
3. 2001) Th2 dominance in nasal mucosa in patients with Wegener’s granulomatosis. Clin. Exp. Immunol. 125, 332-339.
< , C. E. J., Howie, A. J., Drake-Lee, A. B., Savage, C. O. S. (https://doi.org/10.1046/j.1365-2249.2001.125002332.x>
4. 1995) Cell-mediated autoimmunity in patients with Wegener’s granulomatosis (WG). Clin. Exp. Immunol. 100, 186-193.
< , B. E., van der Burg, S. H., Hagen, E. C., van der Woude, F. J., Melief, C. J., Daha, M. R. (https://doi.org/10.1111/j.1365-2249.1995.tb03651.x>
5. 2006) Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. USA 103, 17414-17419.
< , C., Wulff, H., Standifer, N. E., Azam, P., Mullen, K.M., Pennington, M.W., Kolski-Andreaco, A., Wei, E., Grino, A., Counts, D. R., Wang, P. H., LeeHealey, C. J., S Andrews, B., Sankaranarayanan, A., Homerick, D., Roeck, W. W., Tehranzadeh, J., Stanhope, K. L., Zimin, P., Havel, P. J., Griffey, S., Knaus, H. G., Nepom, G. T., Gutman, G. A., Calabresi, P. A., Chandy, K. G. (https://doi.org/10.1073/pnas.0605136103>
6. 2006) Antineutrophil cytoplasmic antibodies. Lancet 368, 404-418.
< , X., Gilabert, A., Font, J. (https://doi.org/10.1016/S0140-6736(06)69114-9>
7. 1991) Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener’s granulomatosis and clinically related disorders. Clin. Exp. Immunol. 83, 379-386.
< , E., Cohen Tervaert, J. W., Horst, G., Huitema, M. G., van der Giessen, M., Limburg, P. C., Kallenberg, C. G. (https://doi.org/10.1111/j.1365-2249.1991.tb05647.x>
8. 1994) T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener’s granulomatosis (WG). Clin. Exp. Immunol. 98, 448-453.
< , E., Stegeman, C. A., Huitema, M. G., Limburg, P. C., Kallenberg, C. G. (https://doi.org/10.1111/j.1365-2249.1994.tb05511.x>
9. 2003) Quantification of regulatory T cells in patients with systemic lupus erythematosus. J. Autoimmun. 21, 273-276.
< , J. C., Martinez, A., Alcocer-Varela, J. (https://doi.org/10.1016/S0896-8411(03)00121-5>
10. 1999) Cytokine profiles in Wegener’s granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum. 42, 742-750.
< , E., Trabandt, A., Muller, A., Wang, G. C., Moosig, F., Paulsen, J., Schnabel, A., Gross, W. L. (https://doi.org/10.1002/1529-0131(199904)42:4<742::AID-ANR18>3.0.CO;2-I>
11. 2006) Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway. Blood 107, 4440-4448.
< , E., Ai, M., Gross, W. L., Wicklein, D., Petersen, A., Lindner, B., Lamprecht, P., Holle, J. U., Hellmich, B. (https://doi.org/10.1182/blood-2005-05-1875>
12. 1999) Prominence of cell-mediated immunity effectors in “pauci-immune” glomerulonephritis. J. Am. Soc. Nephrol. 10, 499-506.
< , M. A., Huang, X. R., Dowling, J. P., Tipping, P. G., Holdsworth, S. R. (https://doi.org/10.1681/ASN.V103499>
13. 1998) The concept of type-1 and type-2 helper T cells and their cytokines in humans. Int. Rev. Immunol. 16, 427-455.
< , G. (https://doi.org/10.3109/08830189809043004>
14. 2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J. Exp. Med. 200, 277-285.
< , M. R., Evans, J. G., Singh, A., Moore, S., Warnes, G., Isenberg, D.A., Mauri, C. (https://doi.org/10.1084/jem.20040165>
15. 1983) Pulmonary vasculitis (Wegener’s granulomatosis). Immunohistochemical study of T and B cell markers. Am. J. Med. 74, 700-704.
< , G. N., Ahmad, M., Tubbs, R. R. (https://doi.org/10.1016/0002-9343(83)91030-6>
16. 1998) Expanded T cell populations in patients with Wegener’s granulomatosis: characteristics and correlates with disease activity. J. Clin. Immunol. 18, 404-413.
< , R., Nityanand, S., Lewin, N., Grunewald, J., Lefvert, A. K. (https://doi.org/10.1023/A:1023230722874>
17. 2006) Characterization of the expanded T-cell populations in patients with Wegener’s granulomatosis. J. Intern. Med. 260, 224-230.
< , R., Wang, X. B., Kakoulidou, M., Lefvert, A. K. (https://doi.org/10.1111/j.1365-2796.2006.01688.x>
18. 1996) T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Clin. Exp. Immunol. 103, 253-258.
< , M. E., Coulthart, A., Pusey, C. D. (https://doi.org/10.1046/j.1365-2249.1996.d01-629.x>
19. 1998) T-cell expansions with conserved T-cell receptor β chain motifs in the peripheral blood of HLA-DRB1*0401 positive patients with necrotizing vasculitis. Blood 92, 3737-3744.
< , J., Halapi, E., Wahlstrom, J., Giscombe, R., Nityanand, S., Sanjeevi, C., Lefvert, A. K. (https://doi.org/10.1182/blood.V92.10.3737>
20. 1994) Evidence for delayed type hypersensitivity mechanisms in glomerular crescentic formation. Kidney Int. 46, 69-78.
< , X. R, Holdsworth, S. R, Tipping, P. G. (https://doi.org/10.1038/ki.1994.245>
21. 2004) New genomic region for Wegener’s granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum. Genet. 114, 468-477.
< , P., Gencik, M., Arning, L., Wieczorek, S., Kunstmann, E., Csernok, E., Gross, W. L., Epplen, J. T. (https://doi.org/10.1007/s00439-004-1092-z>
22. 2005) The PTPN22 620W allele is a risk factor for Wegener’s granulomatosis. Arthritis Rheum. 52, 4039-4043.
< , P., Aries, P., Arning, L., Wagenleiter, S. E, Csernok, E., Hellmich, B., Gross, W. L, Epplen, J. T. (https://doi.org/10.1002/art.21487>
23. 1997) Small-vessel vasculitis. N. Engl. J. Med. 337, 1512-1523.
< , J. C, Falk, R. J. (https://doi.org/10.1056/NEJM199711203372106>
24. 2005) The role of T lymphocytes in ANCA associated vasculitis: neglected or revisited? Clin. Nephrol. 64, 471-474.
< , A. I, van der Woude, F. J., Yard, B. A. (https://doi.org/10.5414/CNP64471>
25. 2001) Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum. 44, 469-473.
< , M., Csernok, E., Müller, A., Metzler, C., Trabandt, A., Gross, W. L. (https://doi.org/10.1002/1529-0131(200102)44:2<469::AID-ANR66>3.0.CO;2-0>
26. 1998) T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA-associated systemic vasculitis and persist during disease remission. Clin. Exp. Immunol. 112, 539-546.
< , W. J., Brooks, C. J., Holder, R., Hughes, P., Adu, D., Savage, C. O. S. (https://doi.org/10.1046/j.1365-2249.1998.00615.x>
27. 2002) Peripheral blood and granuloma CD4+CD28-T cells are a major source of interferon-γ and tumor necrosis factor-α in Wegener’s granulomatosis. Am. J. Pathol. 160, 1717-1724.
< , A., Lamprecht, P., Csernok, E., Mueller, A., Holl-Ulrich, K., Seitzer, U., Moosig, F., Schnabel, A., Gross, W. L. (https://doi.org/10.1016/S0002-9440(10)61118-2>
28. 2005) Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Clin. Exp. Immunol. 141, 201-210.
< , P. (https://doi.org/10.1111/j.1365-2249.2005.02808.x>
29. 2003a) Differences in CCR5 expression on peripheral blood CD4+CD28– T-cells and in granulomatous lesions between localized and generalized Wegener’s granulomatosis. Clin. Immunol. 108, 1-7.
< , P., Bruehl, H., Erdmann, A., Holl-Ulrich, K., Csernok, E. Seitzer, U., Mack, M., Feller, A. C., Reinhold-Keller, E., Gross, W. L., Muller, A. (https://doi.org/10.1016/S1521-6616(03)00121-9>
30. 2003b) Heterogeneity of CD4+ and CD8+ memory T cells in localized and generalized Wegener’s granulomatosis. Arthritis Res. Ther. 5, R25-R31.
< , P., Erdmann, A., Mueller, A., Csernok, E., Reinhold-Keller, E., Holl-Ulrich, K., Feller, A. C, Bruehl, H., Gross, W. L. (https://doi.org/10.1186/ar610>
31. 2006) Effector memory T cells as driving force of granuloma formation and autoimmunity in Wegener’s granulomatosis. J. Intern. Med. 260, 187-191.
< , P., Csernok, E., Gross, W. L. (https://doi.org/10.1111/j.1365-2796.2006.01698.x>
32. 2007) T cell alterations and lymphoid neogenesis favoring autoimmunity in Wegener’s granulomatosis. Arthritis Rheum. 56, 1725-1727.
< , P., Gross, W. L., Kabelitz, D. (https://doi.org/10.1002/art.22693>
33. 1998) Active Wegener’s granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J. Immunol. 160, 3602-3609.
< , B. R, Sneller, M. C, Chua, K. S, Talar-Williams, C., Langford, C. A., Ehrhardt, R. O., Fauci, A. S., Strober, W. (https://doi.org/10.4049/jimmunol.160.7.3602>
34. 2005) Abnormalities of CD4 T cell subpopulations in ANCA-associated vasculitis. Clin. Exp. Immunol. 140, 181-191.
< , S., Neumann, I., Kälsch, A. I., Grimminger, P., Breedijk, A., Birck, R., Schmitt, W., Waldherr, R., Yard, B. A., van Der Woude, F. J. (https://doi.org/10.1111/j.1365-2249.2005.02731.x>
35. 2006) Persistent T cell activation and clinical correlations in patients with ANCA-associated systemic vasculitis. Nephrol. Dial. Transplant. 21, 1825-1832.
< , S., Kälsch, A. I., Grimminger, P., Breedijk, A., Birck, R., Schmitt, W. H., Weiss, C., van der Woude, F. J., Yard, B. A. (https://doi.org/10.1093/ndt/gfl097>
36. 2003) Strong polarization toward Th1 immune response in ANCA-associated glomerulonephritis. Clin. Nephrol. 59, 395-405.
< , K., Tokumoto, M., Nakashima, H., Tsuruya, K., Kashiwagi, M., Kudoh, Y., Fukuda, K., Kanai, H., Akahoshi, M., Otsuka, T., Hirakata, H., Iida, M. (https://doi.org/10.5414/CNP59395>
37. 1998) Costimulatory molecules in Wegener’s granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells. Clin. Exp. Immunol. 114, 113-118.
< , F., Csernok, E., Wang, G., Gross, W. L. (https://doi.org/10.1046/j.1365-2249.1998.00695.x>
38. 2006) Anti-neutrophil cytoplasm-associated glomerulonephritis. J. Am. Soc. Nephrol. 17, 1224-1234.
< , M. D., Harper, L., Williams, J., Savage, C. (https://doi.org/10.1681/ASN.2005080882>
39. 1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17, 138-146.
< , T. R, Sad, S. (https://doi.org/10.1016/0167-5699(96)80606-2>
40. 2000) Localized Wegener’s granulomatosis: predominance of CD26 and IFN-γ expression. J. Pathol. 192, 113-120.
< , A., Trabandt, A., Gloeckner-Hofmann, K., Seitzer, U., Csernok, E., Schönermarck, U., Feller, A. C., Gross, W. L. (https://doi.org/10.1002/1096-9896(2000)9999:9999<::AID-PATH656>3.0.CO;2-M>
41. 1999) Differential B-and T-cell activation in Wegener’s granulomatosis. J. Allergy Clin. Immunol. 103, 885-894.
< , E. R., Stegeman, C. A., Bos, N. A., Kallenberg, C. G., Cohen Tervaert, J. W. (https://doi.org/10.1016/S0091-6749(99)70434-3>
42. 2002) In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3-and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase. Arthritis Rheum. 46, 1894-1904.
< , E. R, Franssen, C. F, Limburg, P. C, Huitema, M. G, Kallenberg, C. G. M., Cohen Tervaert, J. W. (https://doi.org/10.1002/art.10384>
43. 1993) Cellular immune responses and pathogenesis in c-ANCA positive vasculitides. J. Autoimmun. 6, 227-236.
< , N., Petersen, J. (https://doi.org/10.1006/jaut.1993.1020>
44. 1997) CD28 costimulation promotes the production of Th2 cytokines. J. Immunol. 158, 658-665.
< , C. R., Sperlin, A. I., Fields, P. E., Fitch, F. W., Bluestone, J. A. (https://doi.org/10.4049/jimmunol.158.2.658>
45. 2006) NK026680, a novel suppressant of dendritic cell function, prevents the development of rapidly progressive glomerulonephritis and perinuclear antineutrophil cytoplasmic antibody in SCG/Kj mice. Arthritis Rheum. 54, 3707-3715.
< , K., Tokunaka, K., Ichimura, E., Toyoda, E., Abe, F., Yoshida, M., Furukawa, H., Nose, M., Ono, M. (https://doi.org/10.1002/art.22187>
46. 2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6, 345-352.
< , S. (https://doi.org/10.1038/ni1178>
47. 2003) The Th1 and Th2 paradigm in ANCA-associated vasculitis. Kidney Blood Press Res. 26, 215-220.
< , J. S. F., Stegeman, C. A., Kallenberg, C. G. M. (https://doi.org/10.1159/000072987>
48. 2006) Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse. Ann. Rheum. Dis. 65, 1484-1489.
< , J. S., Huitma, M. G., Kallenberg, C. G., Stegeman, C. A. (https://doi.org/10.1136/ard.2005.046219>
49. 2005) Pathogenesis of Wegener’s granulomatosis: current concepts. Expert Rev. Mol. Med. 7, 1-19.
< , P., Sneller, M. C. (https://doi.org/10.1017/S146239940500921X>
50. 1997) Primary systemic vasculitis. Lancet 349, 553-558.
< , C. O., Harper, L., Adu, D. (https://doi.org/10.1016/S0140-6736(97)80118-3>
51. 1992) Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener’s granulomatosis. Association with disease activity. Arthritis Rheum. 35, 1088-1096.
< , W. H., Heesen, C., Csernok, E., Rautman, A., Gross, W. L. (https://doi.org/10.1002/art.1780350914>
52. 2004) Treatment of refractory Wegener’s granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 65, 1440-1448.
< , W. H., Hagen, E. C., Neumann, I., Nowack, R., Flores-Suárez, L.F., van der Woude, F. J.; European Vasculitis Study Group (https://doi.org/10.1111/j.1523-1755.2004.00534.x>
53. 2005) Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 52, 2926-2935.
< , R. A, Di Toma, L., Maggiore, U., Bottero, P., Radice, A., Tosoni, C., Grasselli, C., Pavone, L., Gregorini, G., Monti, S., Frassi, M., Vecchio, F., Corace, C., Venegoni, E., Buzio, C. (https://doi.org/10.1002/art.21250>
54. 1993) Serum markers of T-cell activation in relapses of Wegener’s granulomatosis. Clin. Exp. Immunol. 91, 415-420.
< , C. A., Cohen Tervaert, J. W, Huitema, M. G., Kallenberg, C. G. M. (https://doi.org/10.1111/j.1365-2249.1993.tb05918.x>
55. 1994) Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann. Intern. Med. 120, 12-17.
< , C. A., Tervaert, J. W., Sluiter, W. J., Manson, W. L., de Jong, P. E., Kallenberg, C. G. (https://doi.org/10.7326/0003-4819-120-1-199401010-00003>
56. 2001) Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener’s granulomatosis. Clin. Exp. Immunol. 126, 143-150.
< , K., Moosig, F., Csernok, E., Selleng, K., Gross, W. L., Fleischer, B., Broker, B. M. (https://doi.org/10.1046/j.1365-2249.2001.01575.x>
57. 1999) Th1/Th2 subsets, distinct differences in homing and chemokine receptor expression? Springer Semin. Immunopathol. 21, 263-285.
< , U., Siveke, J., Hamann, A. (https://doi.org/10.1007/BF00812257>
58. 2003) Molecular mechanisms regulating Th1 immune responses. Ann. Rev. Immunol. 21, 713-758.
< , S. J., Sullivan, B. M., Peng, S. L., Glimcher, L. H. (https://doi.org/10.1146/annurev.immunol.21.120601.140942>
59. 2005) Glomerulonephritis, Th1 and Th2: what’s new? Clin. Exp. Immunol. 142, 207-215.
< , P. G, Kitching, A. R. (https://doi.org/10.1111/j.1365-2249.2005.02842.x>
60. 2000) Clonality and longevity of CD4+CD28null T cells are associated with defects in apoptotic pathways. J. Immunol. 165, 6301-6307.
< , A. N, Schirmer, M., Weyand, C. M, Goronzy, J. J. (https://doi.org/10.4049/jimmunol.165.11.6301>
61. 2000) In vitro T lymphocyte responses to proteinase 3 (PR3) and linear peptides of PR3 in patients with Wegener’s granulomatosis (WG). Clin. Exp. Immunol. 122, 504-513.
< , Y. M, Huitema, M. G, Franssen, C. F, van der Zee, R., Limburg, P. C., Kallenberg, C. G. (https://doi.org/10.1046/j.1365-2249.2000.01415.x>
62. 2007) Mechanisms of vasculitis: How pauci-immune is ANCA-associated vasculitis? Nephron Exp. Nephrol. 105, e10-e16.
< , P., Cohen Tervaert, J. W., Heeringa, P. (https://doi.org/10.1159/000096960>
63. 2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. Exp. Med. 199, 971-979.
< , V., Baecher-Allan, C., Weiner, H. L., Hafler, D. A. (https://doi.org/10.1084/jem.20031579>
64. 2003) Shortening of telomeres: Evidence for replicative senescence of T cells derived from patients with Wegener’s granulomatosis. Kidney Int. 63, 2144-2151.
< , S., Iking-Konert, C., Hug, F., Andrassy, K., Hansch, G. M. (https://doi.org/10.1046/j.1523-1755.2003.00037.x>
65. 1997) High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener’s granulomatosis. Am. J. Med. 102, 517-523.
< , G., Hansen, H., Tatsis, E., Csernok, E., Lemke, H., Gross, W. L. (https://doi.org/10.1016/S0002-9343(97)00049-1>
66. 2002) Novel genetic association of Wegener’s granulomatosis with the interleukin 10 gene. J. Rheumatol. 29, 317-320.
, Y., Giscombe, R., Huang, D., Lefvert, A. K. (